egfrm nsclc: should we treat with durvalumab? - asco lung review 2022
Published 2 years ago • 141 plays • Length 7:28Download video MP4
Download video MP3
Similar videos
-
7:54
keytruda combined with anti-vegf treatment:use in patients with advanced nsclc-asco lung review 2022
-
2:22
aegean trial: perioperative durvalumab for nsclc - onctalk lung 2023
-
12:25
adagrasib for previously treated kras g12c nsclc - asco lung review 2022
-
9:34
rybrevant/lazertinib for egfrm acquired resistance - asco lung review 2022
-
6:38
asco 2021 lung recap: poseidon trial: durvalumab /- tremelimumab vs. chemo alone
-
8:13
checkmate 816: combining chemo and opdivo - asco lung review 2022
-
5:46
patritumab deruxtecan: use in previously treated patients without mutations - asco lung review 2022
-
1:42
moa of imfinzi in 1l mnsclc - narrated by debbie irwin
-
6:26
metastatic egfr nsclc: recent developments - targeted therapies in lung cancer 2023
-
5:31
biomarkers in nsclc - targeted therapies in lung cancer 2023
-
7:39
chemotherapy and immunotherapy for patients with kras mutations - asco lung review 2022
-
3:20
egfr mutated nsclc disease progression on osimertinib - 2022 program: targeted therapies forum
-
7:49
alk nsclc treatment options - 2022 program: targeted therapies forum
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
4:02
treatment of egfr mutated nsclc - 2022 program: targeted therapies forum - english
-
4:40
ntrk nsclc: treatment options and side effects - targeted therapies in lung cancer 2023
-
7:35
treatment for patients with egfr nsclc - leading developments & current questions in lung cancer
-
4:22
what is egfr in lung cancer? - 2022 program: targeted therapies forum
-
10:16
overcoming resistance in egfr nsclc - lung cancer onctalk 2022
-
6:20
oncogene-driven metastatic nsclc: frontline treatment & resistance mechanisms - onctalk 2022
-
2:43
pneumonectomy in nsclc - onctalk lung 2023